FDAnews
www.fdanews.com/articles/210305-accure-acnes-laser-system-cleared

Accure Acne’s Laser System Cleared

November 29, 2022

The FDA has cleared Accure Acne’s Accure Laser System to treat mild-to-severe inflammatory acne vulgaris, which is caused by clogged sebaceous glands.

The system uses a 1726 nanometer laser wavelength which selectively targets sebaceous glands using a proprietary pulsing algorithm that controls the thermal depth. The system features temperature monitoring and automated control.

Acne vulgaris is one of the most treated skin conditions, with more than 50 million teens and adults affected annually in the U.S.

Accure expects to make the Accure Laser System available in a limited commercial release to board-certified dermatologists.

View today's stories